China Resources Double-Crane Pharmaceutical Co Ltd. Stock Analysis 600062.SS

China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. The company is headquartered in Beijing, Beijing and currently employs 13,184 full-time employees. The firm operates two segments. The Infusion segment is mainly engaged in the production and sale of infusion products and the provision of services. The Non-Infusion segment is mainly engaged in the production and sale of non-infusion products and the provision of services. The firm's chronic disease business products include compound reserpine triamterene tablets, gliquidone tablets and others. The firm's specialty business products include teniposide injection, busulfan injection and others. The firm's infusion business products include basic infusion, therapeutic infusion, nutritional infusion and other multi-category infusion products. The firm's API business products include valsartan, amlodipine, pregabalin and others.